Abstract
Golimumab belongs to a family of TNF inhibitors which is used in treatment of axial spondyloarthritis. Its efficacy and safety were evaluated in two pivotal randomized controlled studies in patients with active ankylosing spondylitis (GO-RAISE) and non-radiographic axial spondyloarthritis (GO-AHEAD).
The results confirmed good treatment effect comparing to patients treated with placebo. According to recent studies golimumab decrease the level of bone marrow edema on magnetic resonance of sacroiliac joints and spine.
Immunogenicity is lower in patients with axial spondyloarthritis compare to patients with rheumatoid arthritis and the persistence of golimumab is similar to the studies with different TNF inhibitors. Therefore, golimumab pictures safe and effective way for long-term treatment of both non-radiographic and radiographic forms of the disease.